TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01414153
Drug: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months
Study: NCT00156312
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04062045
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B will receive Saline 0,9% through the erector spinae catheter.
Study: NCT01545856
Drug: levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: levodopa use
Study: NCT02807987
Drug: CS-3150
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-3150 1.25 to 2.5, 5mg, orally
Study: NCT01967550
Drug: diclofenac diethylamine, DDEA 2.32% gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01967550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01117220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID) to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
Study: NCT03212937
Drug: ICE Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Ifosfamide 5g/m\^2 on Day 2 (inpatient) or D1 (outpatient) of each 21-day cycle~IV Carboplatin AUC 5 on Day 2 (inpatient) or D1-3 (outpatient) of each 21-day cycle~IV Etoposide 100 mg/m\^2 on Days 1-3 of each 21-day cycle
Study: NCT02255422
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02072811
Drug: Consolidation, I HAM cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days~* Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days
Study: NCT03826550
Drug: Diclofenac Sodium Gel
Normalized name: diclofenac sodium Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twice daily for 60 days. Each patient is expected to receive 120 doses
Study: NCT03826550
Drug: Solaraze 3% Topical Gel
Normalized name: Solaraze 3% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily for 60 days. Each patient is expected to receive 120 doses
Study: NCT01343004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0 mcg subcutaneous daily
Study: NCT01343004
Drug: BA058 80 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA058 80 mcg subcutaneous daily
Study: NCT00313794
Drug: CP-675,206
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
Study: NCT03725553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)as soon as the umbilical cord was clamped.
Study: NCT00176995
Drug: 15% Eflornithine Hdyrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04408586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo looks exactly like the study drug, but it contains no active ingredient
Study: NCT01989897
Drug: diluent, saline with HSA--phenol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01634594
Drug: Group R
Normalized name: Typhus group rickettsia Ab
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01730638
Drug: • TF2 and 68 Ga-IMP-288
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03306030
Drug: Three times dose of 4L PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same as mentioned above. The participants began to drink the first 1.5 L of PEG at 2:00 PM and the second 1.5L of PEG at 8:00PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients take the remaining 1.0 L 4-6 hours before colonoscopy.
Study: NCT01634594
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02257151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03307577
Drug: UHE-101 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream containing investigational drug at a concentration of 1%
Study: NCT00460733
Drug: Calcium & Vitamine D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of calcium and 400 UI of Vitamine D3
Study: NCT01874561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.
Study: NCT00005613
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.
Study: NCT00088374
Drug: [15-O] H2O
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[15-0\] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.
Study: NCT01440621
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
Study: NCT00661115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
Study: NCT03535688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily
Study: NCT02177357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01595997
Drug: DLX105
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
Study: NCT01594983
Drug: LCQ908
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00414102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
Study: NCT00127907
Drug: epinephrine (1 mg/1 mL)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03670953
Drug: IR CD-LD
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator - IR CD-LD
Study: NCT03670953
Drug: IPX203 ER CD-LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational formulation - ER CD-LD
Study: NCT01594983
Drug: Placebo of LCQ908
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of LCQ908
Study: NCT02665845
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids will be given to all patients.
Study: NCT02227693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching 20-mg tablets
Study: NCT01934569
Drug: Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
Study: NCT03718507
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)
Study: NCT00216411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03522441
Drug: Clindamycin 1% Gel
Normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel
Study: NCT03522441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Placebo gel
Study: NCT04148261
Drug: Hydrocortisone Acetate (CORT)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg
Study: NCT04148261
Drug: Epinephrine Sulfate (EPI)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min
Study: NCT01661140
Drug: Methotrexate (stable dose)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose
Study: NCT01661140
Drug: Methotrexate (tapering dose)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
Study: NCT04667351
Drug: 2400 mg/m² 5-fu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU
Study: NCT04667351
Drug: 1200 mg/m² 5-fu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion of oxaliplatin,leucovorin and 1200 mg/m² 5-FU
Study: NCT00838396
Drug: Placebo for XP19986 CR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02103569
Drug: FDC of Norethindrone and Ethinyl Estradiol
Normalized name: ethinyl estradiol / norethindrone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02646072
Drug: Ketorolac tromethamine ophthalmic solution 0.45%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indicated for the treatment of pain and inflammation following cataract surgery.
Study: NCT02170116
Drug: Placebo to BIBR 1048 MS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02736032
Drug: External Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol started on day1 of the cycle for endometrial prepartaion
Study: NCT02509091
Drug: Bronchoalveolar Lavage and Local Amikacin Injection
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: injecting 0.4g of AK in 100 ml to 250 ml, not exceeding 300 ml. And generally, repeat it for 3 to 5 times.
Study: NCT00777972
Drug: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05396742
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT03547622
Drug: MAT taper with placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program
Study: NCT02028715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
Study: NCT02028715
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
Study: NCT02561845
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg, 10mg, 20mg
Study: NCT01324232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
Study: NCT02301975
Drug: Placebo inhalation powders via ELLIPTA inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
Study: NCT02301975
Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
Study: NCT03509350
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
Study: NCT03509350
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
Study: NCT03509350
Drug: Vitamin C Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo to match intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
Study: NCT03509350
Drug: Thiamine Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo to match intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
Study: NCT03509350
Drug: Hydrocortisone Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo to match intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge. Steroids will be used when clinically indicated.
Study: NCT02927522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
Study: NCT02585011
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01357486
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients receiving pravastatin 40 mg - once a day
Study: NCT01357486
Drug: Sorafenib + Pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
Study: NCT00896311
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
Study: NCT01137591
Drug: APAP and NAC combination
Normalized name: acetaminophen / codeine phosphate Oral Suspension [Capital and Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: APAP 650mg and NAC 600mg combination oral tablet administered once
Study: NCT01137591
Drug: APAP and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: APAP 650mg and Placebo combination oral tablet administered once
Study: NCT04030091
Drug: 2 hours humulin R 100 IU/mL PIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described for the Intervention 3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL, the treatment duration is just one hour less.
Study: NCT03086460
Drug: Placebo pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo
Study: NCT01987765
Drug: Relestat Ophthalmic Solution 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
Study: NCT02905331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
Study: NCT01002950
Drug: ACU-4429
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
Study: NCT01002950
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets taken orally once daily for 90 days
Study: NCT00927095
Drug: Continuous OC (EE/DROS)
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous EE(20ug)+DROS(3mg) daily for 3 months
Study: NCT00927095
Drug: Intermittent OC (EE/DROS)
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month
Study: NCT00927095
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily placebo
Study: NCT04087525
Drug: HIP1701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin
Study: NCT04087525
Drug: HGP1809
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin
Study: NCT02905565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
Study: NCT00868283
Drug: 0.9% Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml will be given once daily by intravenous infusion for 10 consecutive days.
Study: NCT00006112
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006112
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006112
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04196868
Drug: Methotrexate treatment
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: per os
Study: NCT00772603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active tablet identical to study drug tablets
Study: NCT00772603
Drug: 2400mg SPN-804
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets containing 600mg OXC XR, identical to non-active tablets
Study: NCT00772603
Drug: 1200mg SPN-804
Approvals — FDA: no, EMA: no, PMDA: no
Description: two active tablets and two non-active tablets, all identical
Study: NCT00996684
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo control will be the microplasmin vehicle without the microplasmin.
Study: NCT00776607
Drug: Tablet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
Study: NCT01607918
Drug: D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
Study: NCT01607918
Drug: D1-D14: (lansoprazole + clarithromycin + amoxicillin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
Study: NCT00938509
Drug: ibuprofen suppositories
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-10 mg/kg/day-suppositories
Study: NCT02489461
Drug: VM-1500
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VM-1500 up to 96 weeks
Study: NCT02489461
Drug: Antiretroviral therapy (ART)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy up to 96 weeks
Study: NCT02425826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
Study: NCT00836004
Drug: Clindamycin 300 mg capsule
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 300 mg
Study: NCT00006468
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006468
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006468
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02153762
Drug: Hylatopic Plus
Normalized name: Hylatopic Plus Aurstat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
Study: NCT00834964
Drug: Effexor® 25 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 25 mg, single-dose fasting
Study: NCT01247909
Drug: Ceftriaxone v penicillin and gentamicin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
Study: NCT01747135
Drug: VTS-270
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00944294
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
Study: NCT00849030
Drug: Anastozole (Arimidex) placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg, orally, once daily
Study: NCT03475459
Drug: NPC-15 and/or Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)
Study: NCT02065154
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes